European Commission Approves Novo Holdings Acquisition of Catalent

Published: 10 Dec 2024

Author: Precedence Research

Share :

European Commission has approved Novo Holdings A/S's acquisition of Catalent, Inc., thus clearing an important milestone in this pending transaction. The two formerly private companies will own the global leader in life sciences solutions by the end of 2024, subject to regulatory and closing conditions. Catalent, a healthcare company, has received European Commission approval for its acquisition of Novo Holdings. This would further change Catalent into a privately held entity managed through Novo Holdings, thus affording stakeholders and customers greater flexibility and more value-based and inspirational solutions. 

As a group of leaders of Catalent, Alessandro Maselli, President and CEO of this great company, expressed his appreciation for the approval and the continuous work-in-progress effort by the Catalent team. Senior Partner Jonathan Levy of Novo Holdings underscored the importance of the acquisition approval, stating that this is a step forward towards achieving the transaction benefits.

This approval by the European Commission for the acquisition of Catalent by Novo Holdings will act as a milestone for both companies in not only enabling Catalent for greater innovative solutions but also improving Novo Holdings' leadership in life sciences investments. It is expected to drive healthcare innovations around the world and improve stakeholders and patients across the globe, even with the usual closing conditions and regulatory clearances.

About Catalent

• Global leader in pharmaceutical, biotech, and consumer health solutions.
• Accelerates over 1,500 partner development programs annually.
• Manufactures 70 billion doses of 8,000 products annually.
• Operates over 50 global sites, and employs 17,000 people, including 3,000 scientists.
• Generated $4.4 billion in revenue in 2024.

About Novo Holdings

• Novo Holdings A/S: Life Sciences Investment Firm
• Owned by Novo Nordisk Foundation.
• Specializes in seed, venture, and growth-stage investments.
• Manages private equity and sustainability initiatives.
• As of 2023, managed assets totaling EUR 149 billion.

Broader Implications of the Acquisition

• Acquisition of Novo Holdings by Catalent
• Enhancement of Catalent capabilities by placing Catalent in a stronger position by tapping into Novo Holdings resources.
• Speeding up innovation in personalized medicines, drugs, and consumer health solutions.
• Carrying the promise of better value for customers, patients, and employees.
• It fits into the mission of Catalent, which is setting transformation in the development and supply of products for patients globally

We’ve prepared a service to support you. please feel free to contact us at sales@precedenceresearch.com | +1 804 441 9344